sameAs
Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimenScaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide componentHuman Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus MacaquesTLR4 and TLR7/8 Adjuvant Combinations Generate Different Vaccine Antigen-Specific Immune Outcomes in Minipigs when Administered via the ID or IN RoutesMiniCD4 microbicide prevents HIV infection of human mucosal explants and vaginal transmission of SHIV(162P3) in cynomolgus macaquesPrevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gelA novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environmentCandidate polyanion microbicides inhibit HIV-1 infection and dissemination pathways in human cervical explants.Microbicides 2006 conference.Aggregate complexes of HIV-1 induced by multimeric antibodies.Dynamic electrophoretic fingerprinting of the HIV-1 envelope glycoprotein.DC-SIGN increases the affinity of HIV-1 envelope glycoprotein interaction with CD4.Improving defences at the portal of HIV entry: mucosal and innate immunity.Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140.Which topical microbicides for blocking HIV-1 transmission will work in the real world?Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responsesFlow virometry analysis of envelope glycoprotein conformations on individual HIV virions.A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine RegimensEnhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routesThe nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cellsPhase I randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginallyInnate immunity against HIV: a priority target for HIV prevention researchEffect of vaginal immunization with HIVgp140 and HSP70 on HIV-1 replication and innate and T cell adaptive immunity in women.In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories.Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues.Critical issues in mucosal immunity for HIV-1 vaccine development.HIV-1 expressing the envelopes of transmitted/founder or control/reference viruses have similar infection patterns of CD4 T-cells in human cervical tissue ex vivoInterleukin-8 levels in seminal plasma in chronic prostatitis/chronic pelvic pain syndrome and nonspecific urethritis.Evaluation of TLR agonists as potential mucosal adjuvants for HIV gp140 and tetanus toxoid in mice.C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitorsAntibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulationMucosal application of gp140 encoding DNA polyplexes to different tissues results in altered immunological outcomes in mice.Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen.Selective transmission of R5 HIV-1 variants: where is the gatekeeper?A "prime-pull" vaccine strategy has a modest effect on local and systemic antibody responses to HIV gp140 in miceIntravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage formsTarget cells in vaginal HIV transmission.HIV-1 infection of human penile explant tissue and protection by candidate microbicides.Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc.Preventing HIV-1 sexual transmission--not sexy enough science, or no benefit to the bottom line?
P50
Q21089693-BF65470B-917A-4B7A-A485-E425A265FB21Q24650458-AC152BE2-EB5B-478E-94B6-651AE338B46EQ27318508-A11E7D12-A4D3-479C-AC9F-79A3C66409DAQ27322386-DBFC72B2-898F-435B-AB41-93D145978D72Q27339377-0A8C173A-513A-43E9-B21B-F183CE868CFDQ28473376-0F189367-7EF5-4A54-8FAB-E0FCD5C99B43Q28476693-32A7DA11-6CB4-4691-8333-776087CEF6B2Q30356032-2C02CCBE-C180-404D-BE04-4CAD2B34F1C1Q30357421-3DDB43AD-8185-4B29-A34D-19BAA07C8C16Q30428633-EE812C79-BAA6-445F-86BE-5633BD497E2CQ30454762-BF13817E-FB3A-4D36-8AA9-2FCCBC4ED49AQ30472149-26D5727B-4264-4B49-AAF6-17DD95E17E31Q30494738-75AEAD79-5C2D-4C07-9631-2A26CF256426Q31076192-BAEF8F3D-C386-4B36-92AC-4A574B9D5E97Q33253661-2B480CA7-5A51-4DCB-84BD-EEDD41E6957AQ33665816-031D9A91-6F70-4FAC-B6D3-EAE34BC7927BQ33680883-69061839-79BD-4C5B-AD15-50CBB640140BQ33720317-E72FCE9A-2C2D-4FF9-9995-8DF284A2F160Q33743758-2A25E823-7A2F-4552-8FB6-3784996D60ABQ33930525-B8670216-AB70-419D-801D-A2C3603D23A2Q34044915-64F6B7B4-385A-4617-ADD0-A1083C2622A5Q34243462-B3115D23-3995-47F6-915B-478DA93D656FQ34261593-AF094141-45E1-477B-8BAA-440718495E59Q34352144-CCF45EBB-B911-433A-8591-CDC4C78ED07AQ34408370-3C747DEF-18CC-4B51-A9BC-78987840658BQ34459985-47E652AA-6395-4106-BC4B-94F63EE7F07DQ34510531-0C5F62D0-D232-4D89-B7D5-836322A42293Q34518430-38EF0315-F22C-4E1D-A254-C9EE4E5B3120Q34524955-D509B266-5E5F-4FEF-AC15-CC72AAE32FBCQ34641781-D43FD13A-E7A9-4BB0-9844-89C91DA29CDBQ34694812-9EFDBDF1-202C-45DD-9CED-8DC69864A04AQ34797176-2B146F5B-BF46-400F-BCCD-D5736B454D56Q34993838-056EE705-8000-4A8A-909F-B9E040624F38Q35018140-C9366FAE-5688-42A5-8C2C-8909A2D2C6BDQ35049110-121A73E2-2C94-430B-90F8-941DBA2A6846Q35061979-2FB0D3E8-1BF2-4471-BFF2-1A2482F1E84CQ35068965-5FE02FBB-9B26-48ED-B3CE-E81DAC944223Q35148241-9C0DEA87-9D75-4C17-8247-148210A959EFQ35563416-5C4BBBD2-642A-4943-BE93-0B5DB4B460E0Q35582241-963C9124-C37E-4386-BCBA-938A6DA2523B
P50
description
Chair in Mucosal Infection and Immunity at Imperial College London
@en
wetenschapper
@nl
name
Robin Shattock
@de
Robin Shattock
@en
Robin Shattock
@es
Robin Shattock
@fr
Robin Shattock
@nl
Robin Shattock
@pt
type
label
Robin Shattock
@de
Robin Shattock
@en
Robin Shattock
@es
Robin Shattock
@fr
Robin Shattock
@nl
Robin Shattock
@pt
altLabel
R. J. Shattock
@en
Robin J Shattock
@en
Robin J. Shattock
@en
Robin John Shattock
@en
prefLabel
Robin Shattock
@de
Robin Shattock
@en
Robin Shattock
@es
Robin Shattock
@fr
Robin Shattock
@nl
Robin Shattock
@pt
P2002
P21
P31
P496
0000-0002-4936-1718
P569
1963-01-01T00:00:00Z